1 December 2010 in Journal of Pharmacology and Pharmacotherapeutics
1 November 2014 in Journal of Thrombosis and Haemostasis
1 January 2010 in Thrombosis and Haemostasis
Nitric oxide (NO) regulates both vascular tone and platelet function. Since thrombotic diseases and their animal models consist of both vascular and platelet components, the functional mechanisms by which NO and endothelial nitric oxide synthase (eNOS) regulate thrombotic events are unclear. Experiments were conducted by measuring collagen-induced aggregation of freely circulating radio-labelled platelets in the pulmonary vasculature of anaesthetised mice via external detection probes. In addition, cardiac haemodynamic function was assessed by invasive catheterisation during thrombotic stimulation. Platelet aggregation responses were shown to occur independently of changes in vessel tone induced by pharmacological vasoconstriction or vasodilatation. Acute NOS inhibition significantly potentiated the amplitude and duration of platelet aggregation and an NO donor had an inhibitory effect. In contrast, in eNOS−/− mice, the amplitude of platelet aggregation was not affected although the response was protracted following moderate thrombotic stimulation. Thrombosis induced changes in haemodynamic performance were sensitive to vasomodulation and were potentiated by both NOS inhibition and in eNOS−/− mice. In conclusion, endogenous NO and exogenously applied NO donors exert an antithrombotic effect in vivo through a direct suppression of platelet aggregation. In contrast, eNOS exerts a powerful antithrombotic effect upon the vascular components of thrombosis but has a more subtle effect on the duration of thrombotic responses that are platelet-mediated. Our data demonstrate the differential roles of eNOS and general NO bioavailability in regulating vascular and platelet activity during thrombosis.
1 January 2008 in Thrombosis and Haemostasis
Identifying and evaluating new therapeutic targets in platelets requires advanced animal models in which platelet responses can be measured directly and in situ.This is important because platelet function is strongly influenced by external factors such as those originating from the vascular endothelium. Our objectives were to record graded, non-lethal thromboembolic platelet responses to platelet agonists in situ in the mouse and to demonstrate an inhibitory effect of aspirin in our model. Radiolabelled platelets were infused into anaesthetized mice and responses to ADP, collagen and thrombin measured as changes in platelet associated counts in miniaturized detection probes placed over the thoracic region. All agonists induced dose-dependent changes in platelet counts due to accumulation of thrombi in the pulmonary vasculature. We confirmed a specific platelet effect by comparing platelet and erythrocyte responses and showing platelet aggregates in the lung vasculature histologically. Simultaneous injection of collagen and adrenaline induced increased and protracted synergistic platelet responses compared with individual injection of these agents and aspirin inhibited collagen-induced responses. We confirmed the clinical relevance of our model by showing that platelet thromboembolism in the mouse, like pulmonary embolism in humans, impaired cardiovascular performance. We present a refined method for measuring platelet agonist dose-responses and thromboembolism in real-time without inducing mortality in the mouse. Our technique will be useful in investigating the molecular determinants of physiological and pathophysiological platelet function in an in-vivo context and will enable investigations of both platelet and non-platelets mediators of thrombus formation.
30 November 2009 in British Journal of Pharmacology
Background and purpose: Although exogenous nitric oxide (NO) clearly modifies platelet function, the role and the source of endogenous NO in vivo remain undefined. In addition, endothelial NO synthase (NOS‐3) critically regulates vessel tone but its role in modulating platelet function is unclear. In this paper we have investigated the roles of endogenous NO and NOS‐3 in regulating platelet function in vivo and determined the functional contribution made by platelet‐derived NO. Experimental approach: We used a mouse model for directly assessing platelet functional responses in situ in the presence of an intact vascular endothelium with supporting in vitro and molecular studies. Key results: Acute NOS inhibition by Nω‐nitro‐L‐arginine methyl ester hydrochloride (L‐NAME) enhanced platelet aggregatory responses to thrombin and platelets were shown to be regulated primarily by NO sources external to the platelet. Elevation of endogenous NOS inhibitors to mimic effects reported in patients with cardiovascular diseases did not enhance platelet responses. Platelet responsiveness following agonist stimulation was not modified in male or female NOS‐3−/− mice but responses in NOS‐3−/− mice were enhanced by L‐NAME. Conclusions and implications: Platelets are regulated by endogenous NO in vivo, primarily by NO originating from the environment external to the platelet with a negligible or undetectable role of platelet‐derived NO. Raised levels of endogenous NOS inhibitors, as reported in a range of diseases were not, in isolation, sufficient to enhance platelet activity and NOS‐3 is not essential for normal platelet function in vivo due to the presence of bioactive NO following deletion of NOS‐3.
25 January 2019 in British Journal of Pharmacology
Background and purpose Some clinical studies have reported increased myocardial infarction in people living with HIV taking the antiretroviral abacavir sulphate (ABC). Given that clinical studies contain confounding variables (e.g. HIV status), we investigated the pharmacological impact of antiretrovirals on platelet function in HIV‐negative volunteers in order to identify mechanisms of increased cardiovascular risk. Experimental approach Platelets were isolated from healthy volunteers and HIV‐negative subjects enrolled on a Phase I clinical trial and platelet function evaluated using aggregometry and flow cytometry. In vivo platelet thromboembolism was monitored in anaesthetised mice. Key results Human platelet aggregation was unaffected by all antiretrovirals tested but ABC treatment led uniquely to increased platelet granule release. ABC also interrupted nitric oxide (NO)‐mediated inhibition of platelet aggregation and increased in vivo aggregation in mice. An alternative antiretroviral, tenofovir, did not affect platelet function. Furthermore, aggregation and activation of platelets isolated from twenty subjects taking clinically‐relevant doses of tenofovir were comparable to baseline samples. Conclusions and implications ABC can enhance platelet activation, independently of HIV status suggesting a potential pharmacological effect that is absent with tenofovir. Mechanistically, we propose that ABC enhances platelet degranulation and interrupts NO‐mediated platelet inhibition. The interaction of ABC with NO signalling is supported by data demonstrating ABC‐mediated enhancement of aggregation in vivo and in vitro responses that persist in the presence of NO. Although an association between ABC and platelet activation has not been confirmed in patients, these findings provide evidence of a mechanistic link between platelet activation and antiretroviral therapy.